FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19
Dear Investor,Please find attached a press release from our partner Regeneron:https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-reviewDo not hesitate to contact us for any further questions.With best regards,
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: COVID-19 | Pharmaceuticals